ANI Pharmaceuticals (ANIP) said Friday that the US Food and Drug Administration has now approved Iluvien to treat chronic non-infectious uveitis affecting the eye's posterior segment.
The company intends to market the implant for chronic NIU-PS in addition to its current indication of diabetic macular edema in the US.
ANI shares were up 1.1% in recent premarket activity.